web analytics
1.2 C
Munich
Friday, December 2, 2022

The Exciting Story of Northwest Biotherapeutics, Inc (OTCMKTS: NWBO)

Northwest Biotherapeutics, Inc (OTCMKTS: NWBO) has been on the rise since reversing off $0.18 lows where the stock has found significant support in the past. NWBO is an exciting Company with a recent history of explosive moves up. The stock used to trade at much higher levels.

Northwest Biotherapeutics, Inc (OTCMKTS: NWBO) is a clinical stage biotechnology company focused on the development of personalized immunotherapy for a broad range of solid tumor cancers. The company has over 150 issued patents and more than 60 pending patent applications worldwide, grouped into 12 patent families. The Company is led by Linda Powers, a successful entrepreneur who worked for many years in corporate finance and restructurings, mergers and acquisitions, joint ventures and intellectual property licensing. Ms. Powers has served as the Chairman of NW Bio since 2007, and as CEO since 2011.

Northwest has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient’s own immune system to attack their cancer. The company’s lead product, DCVax®-L, is designed to treat solid tumor cancers in which the tumor can be surgically removed. This product in an ongoing Phase III trial for newly diagnosed Glioblastome multiforme (GBM). 331 patients have been enrolled in the trial, and enrollment is closed. Patients in the trial are continuing to be treated, and “events” of tumor recurrence and patient deaths are accumulating and being tracked. The trial includes a crossover option, under which patients who were originally assigned to the placebo arm of the trial have an opportunity, when their tumor recurs, to cross over and start receiving DCVax-L. Patients who were originally assigned to the treatment arm may also continue receiving the DCVax-L treatment after their tumor recurs. The patients, the physicians and the Company remain blinded as to which arm of the trial patients were in prior to crossover.

In addition to its patent portfolio, NWBO has obtained Orphan Drug designation for their lead product, DCVax-L for glioma brain cancers. Such designation brings with it a variety of benefits, including potential market exclusivity for seven years in the U.S. and ten years in Europe if our product is the first of its type to reach the market.

February, 2020 (Microcapdaily.com) — Microcapdaily.com is an exciting small caps focused media portal providing in depth content on small cap companies such as Northwest Biotherapeutics, Inc (OTCMKTS: NWBO).

To Find out the inside Scoop on NWBO Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

NWBO is also working on preparations for Phase II trials of DCVax-L for other indications. Northwest’s second product, DCVax®-Direct, is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed, and included treatment of a diverse range of cancers. The Company is working on preparations for Phase II trials of DCVax-Direct.

On December 12 NWBO announced it has further expanded its senior management team with the addition of Ms. Jean M. Davis as Chief Financial Officer, Chief Accounting Officer, and interim Chief Information Officer.

Ms. Davis comes to NW Bio from BDO USA LLP, where she was a Risk Advisory Senior Manager. She is a Certified Public Accountant, Certified Sarbanes-Oxley Expert, Certified Internal Auditor, and Certified Project Management Professional. She obtained her Master of Science in Business with a concentration in Finance and Accounting from Johns Hopkins University.

NWBO operates in the booming global cancer biologics market which is expected to reach USD $87.6 billion by 2024 and is projected to grow substantially over the forecast period from 2017 to 2024. Increasing prevalence of cancer and patent expiry of related drugs is anticipated to boost the oncology biologics market.

We have a Monster Pick Coming. Subscribe Right Now!

Currently trading at a $116 million market valuation NWBO has $1.9 million in the treasury, some revenues reporting $1.5 million in revenues for the 9 months ended September 30, 2019 and significant debt on the books. Northwest is a really exciting company; their lead product, DCVax®-L, is designed to treat solid tumor cancers in which the tumor can be surgically removed. This product in an ongoing Phase III trial for newly diagnosed Glioblastome multiforme (GBM). To Find out the inside Scoop on NWBO Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in NWBO either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.